Connecting you to content on EBSCOhost

Works matching AU Bock, Amy E.

Results: 4

1

Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.

Published in:

Rheumatology & Therapy, 2022, v. 9, n. 3, p. 839, doi. 10.1007/s40744-022-00439-8

By:

Fleischmann, Roy M.;
Bock, Amy E.;
Zhang, Wuyan;
Godfrey, Charles M.;
Vranic, Ivana;
Cronenberger, Carol;
Dokoupilová, Eva

Publication type:

Article

2

Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 10, p. 1166, doi. 10.1002/cpdd.939

By:

Cox, Donna S.;
Alvarez, Daniel F.;
Bock, Amy E.;
Cronenberger, Carol L.

Publication type:

Article

3

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

Published in:

Arthritis Research & Therapy, 2021, v. 23, n. 1, p. 1, doi. 10.1186/s13075-021-02626-4

By:

Fleischmann, Roy M.;
Alvarez, Daniel F.;
Bock, Amy E.;
Cronenberger, Carol;
Vranic, Ivana;
Zhang, Wuyan;
Alten, Rieke

Publication type:

Article

4

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.

Published in:

Arthritis Research & Therapy, 2018, v. 20, n. 1, p. N.PAG, doi. 10.1186/s13075-018-1676-y

By:

Fleischmann, Roy M.;
Alten, Rieke;
Pileckyte, Margarita;
Lobello, Kasia;
Hua, Steven Y.;
Cronenberger, Carol;
Alvarez, Daniel;
Bock, Amy E.;
Sewell, K. Lea

Publication type:

Article